Mayne Pharma Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.2M
Doctors Paid
18,503
Transactions
93,777
2022 Total
$715,061
Payment Breakdown by Category
Research$5.8M (70.7%)
Food & Beverage$1.6M (19.8%)
Consulting$357,949 (4.4%)
Travel$72,519 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.8M | 165 | 70.7% |
| Food and Beverage | $1.6M | 93,177 | 19.8% |
| Consulting Fee | $357,949 | 70 | 4.4% |
| Honoraria | $341,459 | 175 | 4.2% |
| Travel and Lodging | $72,519 | 141 | 0.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,325 | 9 | 0.0% |
| Gift | $1,075 | 1 | 0.0% |
| Education | $95.00 | 38 | 0.0% |
| Entertainment | $29.20 | 1 | 0.0% |
Payments by Type
Research
$5.8M
165 transactions
General
$2.4M
93,612 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Ivermectin Lotion Clinical Endpoint Study | $1.1M | 0 | 10 |
| A Comparative Bioavailability Study Comparing SUBA-itraconazole Capsules Mayne Pharma, Inc. Co-Administered with Omeprazole Delayed-Release Capsules Sandoz Inc. in Healthy Adult Subjects | $631,000 | 0 | 9 |
| ENDEMIC MYCOSES STUDY | $556,745 | 0 | 17 |
| An Open-Label, Randomized, Two-Treatment, Two-Sequence, Two-Period, Cross-over, Multiple-Dose, Steady-State, Oral Bioequivalence Study of SUBA-Itraconazole Capsules 65 mg 2 X 65 mg BID Test and Sporanox Itraconazole Capsules 100 mg 2 X 100 mg BID Reference in Healthy, Adult, Human Subjects under Fed Conditions | $545,492 | 0 | 5 |
| An Open-Label, Randomized, Two-Treatment, Two-Sequence, Two-Period, Cross-over, Multiple-Dose, Steady-State, Food Effect Study of SUBA-Itraconazole Capsules 65 mg 2 X 65 mg BID Test in Healthy, Adult, Human Subjects under Fasting and Fed Conditions | $545,492 | 0 | 7 |
| Permethrin Bioequivalence | $388,911 | 0 | 4 |
| SUBA-INTRACONAZOLE VERSUS CONVENTIONAL ITRACONAZOLE IN THE TREATMENT OF ENDEMIC MYCOSES: A MULTI-CENTER, OPEN-LABEL, RANDOMIZED COMPARATIVE TRIAL | $304,544 | 0 | 12 |
| SUBA-Intraconazole VS Conventional Itraconazole in the Treatment of Endemic Mycoses | $229,200 | 0 | 1 |
| An Open-Label, Randomized, 2- Treatment, 2-Sequence, 2-Period, Crossover, MD, Oral BE Study of Lozanoc Itraconazole Capsules 65 mg 2 X 65 mg Test and Sporanox Itraconazole Capsules 100 mg 2 X 100 mg Reference Administered 3 Times Daily 8 Hours apart from Days 1-3 and Once a Day 2 X 65 mg of Test2 X 100 mg of Reference on Day 4 in Healthy, dult, Human Subjects, under Fed Conditions | $170,478 | 0 | 3 |
| SORILUX PEDIATRIC | $128,191 | 0 | 15 |
| SORILUX5FUCRYO COMBINATION THERAPY | $65,000 | 0 | 1 |
| A multicenter, open-label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005 in pediatric subjects ages 2 to 11 years with plaque psoriasis | $29,963 | 0 | 7 |
| OPEN-LABEL RANDOMIZED CLINICAL TRIAL OF DOXYCYCLINE PEP TO REDUCE BACTERIAL STIS AMONG MSM LIVING WITH HIV AND HIV-UNINFECTED MSM OR PREP. | $28,230 | 0 | 1 |
| DOXY PEP GRANT | $28,230 | 0 | 1 |
| Lamellar Ichthyosis Phase II Study | $15,000 | 4 | 4 |
| MSG-15 | $13,550 | 0 | 2 |
| CASE STUDY OF COMBO THERAPY LEXETTESORILUX FOR TREATMENT OF SCALP PSORIASISSEBOPSORIASIS | $7,707 | 1 | 2 |
| SORILUX ADOLESCENT | $7,235 | 0 | 6 |
| LAMELLAR ICHTHYOSIS PHASE II | $5,625 | 2 | 2 |
| Efficacy of tazarotene foam vs vehicle in treatment of facial photodamage | $5,376 | 1 | 1 |
| Use of Fabior for keratoderma for psorisis | $3,226 | 1 | 1 |
| Single point, randomized, evaluator blinded within subject single center evaluation of the vasoconstrictive properties of halobetasol proprionate foam 0.05 in healthy adults | $2,748 | 1 | 3 |
| Phase IIb open label trial of SUBA-itraconazole in subjects with basal cell carcinoma nevus syndrome BCCNS | $2,600 | 0 | 1 |
| SUBA-INTRACONAZOLE VERSUS CONVENTIONAL ITRACONAZOLE IN THE TREAMENT OF EDEMIC MYCOSES: A MULTI-CENTER, OPEN-LABEL, TADOMIZED COMAPARATIVE TRIAL. | $1,600 | 0 | 1 |
| A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005, Applied Under Maximal-Use Conditions in Adolescent subjects Ages 12 to 16 Years with Plaque Psoriasis | $1,000 | 0 | 1 |
| AN OPEN LABLE EVALUATION OF THE ADRENAL SUPPRESSION POTENTIAL AND PHARMACOKINETIC PROPERTIES OF TWICE DAILY OF HALOBETASOL PROPIONATE FOAM, 0.05% IN SUBJECTS 12 TO LESS THAN 18 YEARS OF AGE WITH PLAQUE PSORIASIS RECEIVING TWO WEEKS OF TREATMENT | $253.80 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 7
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Amy Bumgardner, Md, MD | Dermatology | The Woodlands, TX | $973.36 | $0 |
| Rex Largen, Md, MD | Dermatology | Lincoln, NE | $972.46 | $0 |
| David Hensley, M.d, M.D | Dermatology | Arlington, TX | $969.51 | $0 |
| Dr. Patrick Keehan, D.o, D.O | Dermatology | Fort Worth, TX | $966.98 | $0 |
| Mrs. Carolyn Carroll, Md, MD | Dermatology | Clinton, CT | $962.09 | $0 |
| Dr. Cylburn Soden, M.d., M.a, M.D., M.A | MOHS-Micrographic Surgery | Laurel, MD | $961.98 | $0 |
| Christopher Kling, M.d, M.D | Dermatology | Wildwood, MO | $950.77 | $0 |
| Mr. David Spencer, M.d, M.D | Specialist | Winston Salem, NC | $948.19 | $0 |
| Robert Hartman, M.d, M.D | Dermatology | Encino, CA | $944.51 | $0 |
| Dr. Cheryl Effron, M.d, M.D | Specialist | Anaheim, CA | $939.42 | $0 |
| Heather Richmond, M.d, M.D | Dermatology | Houston, TX | $936.36 | $0 |
| Kyle Anderson, Md, MD | Dermatology | Leawood, KS | $918.20 | $0 |
| Dr. Michael Zaycosky, D.o, D.O | Dermatology | Fairview, PA | $909.11 | $0 |
| Dr. John Vine, M.d, M.D | Dermatology | Princeton, NJ | $907.88 | $0 |
| Barbara Dehn, Rn, Ms, Np, RN, MS, NP | Women's Health | Mountain View, CA | $900.00 | $0 |
| Dr. Alissa Fox, M.d, M.D | Dermatology | Branchburg, NJ | $887.54 | $0 |
| Riley Greene, Md, MD | Dermatology | Littleton, CO | $877.99 | $0 |
| Neil Niren, Md, MD | Dermatology | Orlando, FL | $869.97 | $0 |
| Dr. Rania Agha, M.d, M.D | Dermatology | Oakbrook Terrace, IL | $868.75 | $0 |
| Vaughan Graves, Md, MD | Dermatology | Phila, PA | $867.70 | $0 |
| Dr. Todd Colonna, Md, MD | Dermatology | Rockville, MD | $855.19 | $0 |
| David Lemchak, Do, DO | Family Medicine | Altoona, PA | $852.64 | $0 |
| Mrs. Debra Grayman, M.d, M.D | Dermatology | Orlando, FL | $852.06 | $0 |
| Ming Jih, Md, MD | Dermatology | Bellaire, TX | $850.88 | $0 |
| Dr. Christian Millett, M.d, M.D | Dermatology | Alexandria, VA | $842.80 | $0 |
Ad
Top Products
- TOLSURA $1.2M
- DORYX $1.0M
Associated Products (10)
- TOLSURA $1.2M
- DORYX $1.0M
- ELIMITE $388,911
- SORILUX $356,083
- TRIMETHOPRIM $99,000
- FABIOR $61,022
- NORTRIPTYLINE HYDROCHLORIDE 10MG $59,244
- LEXETTE $29,584
- TOLSURA - 60 CAPSULE $12,500
- MICROGESTIN $11,775
Payment Categories
- Food & Beverage $1.6M
- Consulting $357,949
- Travel & Lodging $72,519
- Research $5.8M
About Mayne Pharma Inc.
Mayne Pharma Inc. has made $8.2M in payments to 18,503 healthcare providers, recorded across 93,777 transactions in the CMS Open Payments database. In 2022, the company paid $715,061. The top product by payment volume is TOLSURA ($1.2M).
Payments were distributed across 162 medical specialties. The top specialty by payment amount is Dermatology ($854,626 to 3,584 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($357,949), Research ($5.8M), Travel & Lodging ($72,519).
Mayne Pharma Inc. is associated with 10 products in the CMS Open Payments database, including TOLSURA, DORYX, and ELIMITE.